VERIGRAFT accepted as member in CAMP

VERIGRAFT is happy to announce that we have become members in CAMP (Centre for Advanced Medical Products), a newly-formed prestigious Swedish national center for advanced therapies.

https://www.vinnova.se/en/p/centre-for-advanced-medical-products/

Advanced therapies based on genes, cells or tissues (ATMPs) have great potential to generate completely new ways of treating or even curing diseases. The Center for Advanced Medical Products (CAMP) focuses on the science, technology and infrastructure required to implement ATMPs from laboratory to clinical practice. The center also addresses the systems and organizational challenges identified as obstacles to the development of the ATMP field in Sweden. Integration of preclinical, clinical, technical and other scientific areas, with commercialization skills, will accelerate research implementation, new patient treatments and industrial growth. The project will optimize cooperation between ATMP infrastructure and academy / healthcare activities as well as commercial preclinical and clinical R&D. This will facilitate further development and commercialization of ATMP and increase Sweden’s competitiveness in this area.

VERIGRAFT nominated for SwedenBIO Award 2018

Gothenburg May 16, 2018
We are proud to announce that VERIGRAFT has been nominated for the SwedenBIO Award 2018. The prize is awarded to a life-science company that has demonstrated accomplishments and achievements beyond the ordinary and contributed to a positive interest in the industry. SwedenBIO Award is the Swedish bioindustry’s own award. The jury consists of SwedenBIO’s Board and a representative of the price sponsor, the global life science investment fund HealthCap AB.
SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 230 members,

http://swedenbio.se/information-in-english/

VERIGRAFT wins a major grant for the development of its novel P-TET production platform

Gothenburg, November 1, 2017

Research Institutes of Sweden (RISE) and VERIGRAFT today announce they have been granted support for a joint project with the title “Production Platform for Personalized Tissue-Engineered Transplants”. The project will be financed by Swedish governmental Vinnova with SEK 5M. The general aim of the project is to develop a tissue manufacturing platform to bring VERIGRAFT´s technology to a broader industrial application within regenerative medicine. Thereby the availability of transplantable organs and tissues will be dramatically increased.

“We are extremely pleased about having this project proposal granted, since it allows our tissue engineering platform to reach another level of industrialization. Together with our strong and committed partner RISE, adding synergistic technological skills to the program, our technology will be more widely applicable for a series of hitherto uncured severe diseases. This will certainly be a key project for the whole field of advanced therapies and regenerative medicine,” says Dr Petter Björquist, CEO of VERIGRAFT.

VERIGRAFT is a regenerative medicine company, located in Gothenburg, Sweden. The company generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogeneic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration and peripheral nerve repair.

RISE Research Institutes of Sweden is fully owned by the Swedish state. RISE supports all manner of innovative processes, and is instrumental in developing the future-proofing of products, technologies, and services. Through collaboration with academia, industry and the public sector, RISE contributes to the competitiveness of the Swedish business community on an international level.

Vinnova is a Swedish government agency working under the Ministry of Enterprise and Innovation and acts as the national contact agency for the EU Framework Program for R&D. Vinnova is also the Swedish government’s expert agency within the field of innovation policy. Vinnova was founded in January 2001, and about 200 people work in their offices in Stockholm and Brussels.

VERIGRAFT is proud to be a member of the SME Champions League

VERIGRAFT just kicked off its core project “Personalized Tissue-Engineered Veins (P-TEV) as the first Cure for Patients with Chronic Venous Insufficiency” that was awarded a grant of 2 184 603,75 Euro from the Horizon 2020 SME instrument of the European Commission.  This funding supports the Phase I/II clinical development of VERIGRAFT’s lead product.

“The SME Instrument funding represents an important element on our way to the next level of development and we are very proud to have been promoted to the SME Champions league. The VERIGRAFT team is very thankful for this reward of our rock-solid commitment and we are highly motivated to make this project a great success. This funding will facilitate our high ambitions to develop novel products that can help millions of patients with today incurable diseases.” says Dr. Petter Björquist, CEO of VERIGRAFT.

VERIGRAFT is a biotechnology company, located in Gothenburg, Sweden. The company generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogeneic tissue is patient-individualized by a combination of DC (decellularization) and RC (reconditioning/recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration and peripheral nerve repair.

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over 7 years (2014 to 2020. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation and to take great ideas from the lab to the market.

 

For more information, please contact: Petter Björquist, CEO, petter.bjorquist@verigraft.com

VERIGRAFT receives grant for the development of personalized tissue-engineered arteries

Gothenburg, June 7, 2017

University of Gothenburg, Research Institutes of Sweden (RISE) and VERIGRAFT were granted support for a collaborative project with the title “Personalized Tissue Engineered Arteries (P-TEA) as a Novel Cure for Cardiovascular Disease”. The project’s total budget of 2,3 million SEK will be supported by Swelife, Medtech4Health and by the region Västra Götaland with 700 000 SEK each. The project will perform a proof of concept study in large animals, characterize P-TEA in vitro to generate preclinical documentation and undertake a technology transfer to industrial GMP production of P-TEA.

“We are very happy about this grant, because it allows us to generate important safety data to bring our product one step closer to the phase of clinical development. Furthermore, this will be a key project for the whole field of regenerative medicine, generating unique in vivo data. Together with our strong and committed partners, we will make our ambitions become true in this innovation project.” says Dr Petter Björquist. CEO of VERIGRAFT.

VERIGRAFT is a regenerative medicine company, located in Gothenburg, Sweden. The company generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogeneic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration and peripheral nerve repair.

The University of Gothenburg is one of the largest universities in the Nordic countries with 37000 students and 6000 staff members and Sahlgrenska University Hospital is associated with the university as a teaching hospital.
RISE Research Institutes of Sweden is fully owned by the Swedish state. RISE supports all manner of innovative processes, and is instrumental in developing the future-proofing of products, technologies, and services. Through collaboration with academia, industry and the public sector, RISE contributes to the competitiveness of the Swedish business community on an international level.

Swelife and Medtech4Health are national strategic innovation programs, funded by the Swedish Government via the Swedish innovation agency, Vinnova. Swelife and Medtech4Health support projects where healthcare, academia and industry collaborate across organizational boundaries and between regions to achieve long-term effects that benefit Swedish Life Science and, in turn, public health.

Region Västra Götaland is a region in West Sweden with the assignment to contribute to a thriving region as a good place to live and work and for future generations to grow up in.